Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

THG 113

Drug Profile

THG 113

Alternative Names: PDC-31; PDC-41; PHG 113; THG113.31

Latest Information Update: 14 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theratechnologies
  • Developer PDC Biotech
  • Class Peptides
  • Mechanism of Action Prostaglandin F2 alpha antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dysmenorrhoea; Preterm labour

Most Recent Events

  • 10 Dec 2012 PDC Biotech completes a phase I trial in Dysmenorrhoea in Austria and Germany (NCT01250587)
  • 24 Jan 2012 Phase-I development is ongoing in Austria and Germany
  • 12 May 2008 THG 113 licensed to PDC Biotech worldwide for the treatment of Dysmenorrhoea and prevention of Preterm labour
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top